| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-01-29 |
| タイトル |
|
|
タイトル |
Effectiveness and Safety of Radium-223 for Bone-Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
キーワード |
effectiveness |
| キーワード |
|
|
言語 |
en |
|
キーワード |
prostate cancer |
| キーワード |
|
|
言語 |
ja |
|
キーワード |
radium‐223 |
| キーワード |
|
|
言語 |
en |
|
キーワード |
safety |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
| 著者 |
Shiota, Masaki
Tatarano, Shuichi
Kamba, Tomomi
賀本, 敏行
WEKO
9783
e-Rad_Researcher
00281098
| ja |
賀本, 敏行
宮崎大学
|
| ja-Kana |
カモト, トシユキ
|
| en |
Kamoto, Toshiyuki
University of Miyazaki
|
Search repository
Igawa, Tsukasa
Masumori, Naoya
Uemura, Hirotsugu
Mitsunari, Kensuke
Sumiyoshi, Takayuki
Uemura, Hiroji
Higashijima, Katsuyoshi
| en |
Higashijima, Katsuyoshi（Personal）
University of Occupational and Environmental Health
|
Search repository
Tokunaga, Shoji
Eto, Masatoshi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Radium-223 dichloride (Ra-223) improves survival in bone-metastatic castration-resistant prostate cancer (mCRPC). However, prospective real-world data are limited, particularly regarding treatment outcomes, predictors of completing six cycles, and integration with subsequent therapies. The KYUCOG-1901 study was a prospective multicenter observational study at 19 Japanese institutions. Patients with mCRPC and ≥ 2 bone metastases received up to six cycles of Ra-223. Effectiveness was assessed by PSA, alkaline phosphatase (ALP), time to visceral metastasis, time to cytotoxic chemotherapy, radiographic progression-free survival (PFS), and overall survival (OS). Safety was evaluated using CTCAE v5.0. Of 101 enrolled, 93 patients were analyzed. Median follow-up was 25.2 months. Early discontinuation was associated with high baseline PSA, ALP, LDH, and symptomatic disease. Subsequent therapies, including taxanes and androgen receptor signaling inhibitors (ARSIs), were administered in most patients. Maximum PSA and ALP declines of ≥ 30% were achieved in 16 (17.2%) and 39 (41.9%) patients, respectively. Median time to visceral metastasis, time to cytotoxic chemotherapy, radiographic PFS (rPFS), and OS were 32.9, 13.7, 8.8, and 23.0 months, respectively. Grade ≥ 3 adverse events occurred in 36.5%. No treatment-related deaths were reported. Ra-223 was effective and well tolerated in Japanese mCRPC patients. Early initiation in less symptomatic patients with lower disease burden may maximize benefit, and integration with subsequent therapies appears feasible. Trial Registration: University Hospital Medical Information Network Clinical Trials Registry UMIN000040358. |
|
言語 |
en |
| 書誌情報 |
en : Cancer science
発行日 2025-12-04
|
| 出版者 |
|
|
出版者 |
Wiley |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
13497006 |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13479032 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1111/cas.70293 |
| 権利 |
|
|
権利情報 |
© 2025 The Author(s). |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
Fulltext (366 KB)
.png)
